CVS Health (CVS) Shares Sold by Bronfman E.L. Rothschild L.P.

Bronfman E.L. Rothschild L.P. lowered its position in shares of CVS Health (NYSE:CVS) by 16.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,809 shares of the pharmacy operator’s stock after selling 2,630 shares during the quarter. Bronfman E.L. Rothschild L.P.’s holdings in CVS Health were worth $859,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Wealthcare Advisory Partners LLC boosted its position in shares of CVS Health by 330.3% during the 3rd quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock worth $105,000 after purchasing an additional 991 shares in the last quarter. Wagner Wealth Management LLC bought a new position in shares of CVS Health during the 4th quarter worth about $114,000. Avestar Capital LLC bought a new position in shares of CVS Health during the 4th quarter worth about $122,000. Focused Wealth Management Inc boosted its position in shares of CVS Health by 90.5% during the 4th quarter. Focused Wealth Management Inc now owns 1,781 shares of the pharmacy operator’s stock worth $129,000 after purchasing an additional 846 shares in the last quarter. Finally, Cerebellum GP LLC bought a new position in shares of CVS Health during the 4th quarter worth about $130,000. 83.96% of the stock is currently owned by institutional investors and hedge funds.

NYSE:CVS opened at $65.76 on Friday. The company has a quick ratio of 1.88, a current ratio of 2.37 and a debt-to-equity ratio of 1.59. The stock has a market capitalization of $66.94 billion, a price-to-earnings ratio of 11.15, a PEG ratio of 0.98 and a beta of 1.02. CVS Health has a 52 week low of $65.60 and a 52 week high of $66.34.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, May 2nd. The pharmacy operator reported $1.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.39 by $0.09. The firm had revenue of $45.69 billion during the quarter, compared to analyst estimates of $45.77 billion. CVS Health had a net margin of 3.59% and a return on equity of 17.45%. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the business posted $1.17 EPS. equities analysts forecast that CVS Health will post 6.99 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, May 3rd. Shareholders of record on Monday, April 23rd were paid a $0.50 dividend. The ex-dividend date of this dividend was Friday, April 20th. This represents a $2.00 annualized dividend and a yield of 3.04%. CVS Health’s dividend payout ratio (DPR) is 33.90%.

A number of equities analysts have recently issued reports on CVS shares. Cowen reissued an “outperform” rating and set a $99.00 price objective (up previously from $81.00) on shares of CVS Health in a research report on Thursday, January 18th. Mizuho set a $95.00 price target on shares of CVS Health and gave the company a “buy” rating in a research report on Wednesday, January 24th. Needham & Company LLC raised shares of CVS Health from a “buy” rating to a “strong-buy” rating and raised their price target for the company from $88.00 to $100.00 in a research report on Tuesday, January 30th. ValuEngine cut shares of CVS Health from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Royal Bank of Canada set a $89.00 price target on shares of CVS Health and gave the company a “buy” rating in a research report on Thursday, February 8th. Three research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $86.27.

In other news, Director C David Brown II acquired 10,000 shares of the firm’s stock in a transaction on Friday, May 4th. The stock was purchased at an average price of $61.99 per share, for a total transaction of $619,900.00. Following the purchase, the director now owns 101,252 shares in the company, valued at approximately $6,276,611.48. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.53% of the company’s stock.

CVS Health Profile

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply